Pathophysiology and therapeutic development for bisphosphonate-related osteonecrosis of the jaw
| Project/Area Number |
25870523
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | ビスフォスフォネート製剤 / 顎骨壊死 / 免疫 / 骨壊死 / マクロファージ / リンパ管内皮細胞 / ONJ / 受容体 / 免疫反応 / 炎症 / 破骨細胞 / 口腔外科学一般 / 免疫・感染・炎症 / 抗がん剤 / 歯科補綴学 |
|---|
| Outline of Final Research Achievements |
Bisphosphonate-related osteonecrosis of the jaw (BR-ONJ) mainly occurs following tooth extraction with patients taking oral and/or intravenous bisphosphonates. However, the mechanisms of BR-ONJ is unclear. The aim of this study was to address pathophysiology of BR-ONJ using mouse ONJ model in the combination of intravenous bisphosphonate treatment, chemotherapy and tooth extraction. This model indicated that immune suppression might be associated with BR-ONJ due to some immune-related cells and proteins. This findings may contribute to the development of ONJ therapy.
|
Report
(3 results)
Research Products
(18 results)
-
-
-
-
-
-
-
-
[Presentation] Successful treatment of advanced bisphosphonate-related osteonecrosis of the jaw, BRONJ, with an adjunctive teriparatide therapy.2014
Author(s)
Kakehashi S, Ando T, Minamizato T, Kuroshima S, Hayashida S, Yanamoto S, Umeda M, Asahina I
Organizer
The XXII Congress of the European Association for Cranio-Maxillo-Facial Surgery congress
Place of Presentation
Prague, Czech Republic
Year and Date
2014-09-23 – 2014-09-26
Related Report
-
-
-
-
-
-
-
-
-
-
